Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) is expected to announce its Q4 2025 resultson Monday, March 30th. Analysts expect the company to announce earnings of ($0.4322) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 11, 2026 at 7:00 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last posted its quarterly earnings results on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Stock Down 0.2%

Shares of SGMT stock opened at $4.82 on Monday. The firm has a 50 day moving average of $5.66 and a 200-day moving average of $6.52. Sagimet Biosciences has a 52 week low of $1.73 and a 52 week high of $11.41. The company has a market cap of $157.04 million, a price-to-earnings ratio of -3.07 and a beta of 3.35.

Analyst Ratings Changes

Several equities research analysts have recently commented on SGMT shares. Guggenheim initiated coverage on Sagimet Biosciences in a report on Tuesday, February 3rd. They set a “buy” rating and a $27.00 price objective for the company. Barclays assumed coverage on shares of Sagimet Biosciences in a report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Thursday, January 22nd. Wall Street Zen upgraded Sagimet Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Sagimet Biosciences in a research report on Wednesday, March 11th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $26.00.

Insider Buying and Selling

In other Sagimet Biosciences news, CEO David Happel sold 12,101 shares of Sagimet Biosciences stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total value of $64,861.36. Following the sale, the chief executive officer owned 677,621 shares of the company’s stock, valued at approximately $3,632,048.56. The trade was a 1.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 14.70% of the company’s stock.

Institutional Investors Weigh In On Sagimet Biosciences

Hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new stake in Sagimet Biosciences in the first quarter worth $105,000. Geode Capital Management LLC increased its stake in shares of Sagimet Biosciences by 0.6% in the second quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock worth $2,023,000 after purchasing an additional 1,600 shares in the last quarter. American Century Companies Inc. raised its position in shares of Sagimet Biosciences by 8.9% in the second quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock valued at $322,000 after purchasing an additional 3,454 shares during the period. XTX Topco Ltd raised its position in shares of Sagimet Biosciences by 137.0% in the second quarter. XTX Topco Ltd now owns 25,624 shares of the company’s stock valued at $195,000 after purchasing an additional 14,813 shares during the period. Finally, Jump Financial LLC purchased a new stake in shares of Sagimet Biosciences during the 2nd quarter valued at approximately $1,130,000. Institutional investors own 87.86% of the company’s stock.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.